Ergoteles’s Cellectis CLLS Stock Holding History

Ergoteles’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,365	Closed	-$40.7K	–	1328
2022 Q4	$40.7K	Buy	+19,365	New	+$43.9K	﹤0.01%	1316

Other funds holding CLLS

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Ergoteles's CLLS Position: Q1 2023 in Review

Ergoteles sold out of Cellectis (CLLS) in Q1 2023, closing a stake of 19,365 shares — an estimated $40.7K sold.

Ergoteles first reported a position in CLLS in Q4 2022 and held it in 1 quarter. The position peaked at $40.7K in Q4 2022. 34 funds tracked by Wall St. Rank hold CLLS as of Q1 2023.

Ergoteles reported no remaining Cellectis position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 19,365 Cellectis shares in Q1 2023, an estimated $40.7K.
Ergoteles first reported a position in Cellectis in Q4 2022 and held it in 1 quarter.
Ergoteles's Cellectis position peaked at $40.7K in Q4 2022.
34 funds tracked by Wall St. Rank held Cellectis as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.